title: [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
abstract: Visualization of malignant lymphomas and granulomatous disease is possible by [111In-DTPA-D-Phe1]octreotide scintigraphy through binding of the radioligand to somatostatin receptors on activated leukocytes. Because thyroidal and orbital tissues are infiltrated by activated leukocytes in Graves' disease, a cross-sectional study to visualize disease activity with [111In-DTPA-D-Phe1]octreotide scintigraphy was performed. A correlation between thyroidal [111In-DTPA-D-Phe1]octreotide accumulation and free T4 (disease expression) and thyroid binding-inhibiting immunoglobulins (disease activity) is present in untreated hyperthyroid Graves' disease. There is also a correlation between orbital [111In-DTPA-D-Phe1]octreotide uptake and the clinical activity score (disease activity) and total eye score (disease expression), respectively, in Graves' orbitopathy. Visualization of thyroidal and orbital Graves' disease is feasible, but further investigation is necessary to establish the role of [111In-DTPA-D-Phe1]octreotide scintigraphy in representing disease activity and expression and in predicting therapeutical outcome.
authors.affiliation: Department of Internal Medicine III, Erasmus University Hospital, Rotterdam, The Netherlands.
authors.forename: P T
authors.initials: PT
authors.lastname: Postema
authors.forename: E P
authors.initials: EP
authors.lastname: Krenning
authors.forename: R
authors.initials: R
authors.lastname: Wijngaarde
authors.forename: P P
authors.initials: PP
authors.lastname: Kooy
authors.forename: H Y
authors.initials: HY
authors.lastname: Oei
authors.forename: W A
authors.initials: WA
authors.lastname: van den Bosch
authors.forename: J C
authors.initials: JC
authors.lastname: Reubi
authors.forename: W M
authors.initials: WM
authors.lastname: Wiersinga
authors.forename: H
authors.initials: H
authors.lastname: Hooijkaas
authors.forename: T
authors.initials: T
authors.lastname: van der Loos
mesh_terms: D005123:Eye / Q000000981:diagnostic imaging* / Q000378:metabolism; D005128:Eye Diseases / Q000000981:diagnostic imaging* / Q000209:etiology / Q000628:therapy; D006111:Graves Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D007205:Indium Radioisotopes; D008713:Methimazole / Q000627:therapeutic use; D015282:Octreotide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D013961:Thyroid Gland / Q000000981:diagnostic imaging* / Q000378:metabolism; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D007205:Indium Radioisotopes; C071632:SDZ 215-811; D008713:Methimazole; D004369:Pentetic Acid; D013974:Thyroxine; D015282:Octreotide